Lack of effect of propranolol in the treatment of lymphangioma in two children

Pediatric Dermatology

Volumn 30, Issue 3, 2013, Pages 383-385

  Maruani, Annabel ^a   Brown, Shanna ^b   Lorette, Gerard ^a   Pondaven Letourmy, Soizick ^c   Herbreteau, Denis ^a   Eisenbaum, Allan ^b,d  

^a UNIVERSITÉ DE TOURS   (France)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROPRANOLOL;

ARTICLE; CARBON DIOXIDE LASER; CASE REPORT; CHILD; CONGENITAL MALFORMATION; CYSTIC LYMPHANGIOMA; DRUG EFFECT; FACIAL COMPLEX LYMPHANGIOMA; HUMAN; LARYNX; LYMPHANGIOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARYNX; PRESCHOOL CHILD; PRIORITY JOURNAL; TELANGIECTASIA; TONGUE; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; CHILD, PRESCHOOL; FACE; HUMANS; LYMPHANGIOMA; LYMPHATIC ABNORMALITIES; MALE; PROPRANOLOL; TONGUE; TREATMENT FAILURE; VASCULAR MALFORMATIONS; VASODILATOR AGENTS;

EID: 84876911160     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/j.1525-1470.2012.01864.x     Document Type: Article

References (15)

1. Perkins J, Manning S, Tempero R, et al., Lymphatic malformations: current cellular and clinical investigations. Otolaryngol Head Neck Surg 2010; 142: 789-794.
2. Butler M, Isogai S, Weinstein B,. Lymphatic development. Birth Defects Res C Embryo Today 2009; 87: 222-231.
3. Hayasaki A, Nakamura H, Hamasaki T, et al., Successful treatment of intraorbital lymphangioma with tissue fibrin glue. Surg Neurol 2009; 72: 722-724.
4. Castañõon M, Margarit J, Carrasco R, et al., Long-term follow-up of nineteen cystic lymphangiomas treated with fibrin sealant. J Pediatr Surg 1999; 34: 1276-1279. (Pubitemid 29383575)
5. Leboulanger N, Roger G, Caze A, et al., Utility of radiofrequency ablation for haemorrhagic lingual lymphangioma. Int J Pediatr Otorhinolaryngol 2008; 72: 953-958.
6. Leauté-Labreze C, Dumas de la Roque E, Hubiche T, et al., Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 24: 2649-2651. (Pubitemid 351831393)
7. Cheng J, Gole G, Sullivan T,. Propranolol in the management of periorbital infantile haemangioma. Clin Experiment Ophthalmol 2010; 38: 547-553.
8. Maby-El Hajjami H, Petrova TV,. Developmental and pathological lymphangiogenesis: from models to human disease. Histochem Cell Biol 2008; 130: 1063-1078.
9. Partanen T, Alitalo K, Miettinen M,. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 1999; 86: 2406-2412. (Pubitemid 30010384)
10. Ferrara N,. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 24: 513-524.
11. D'Angelo G, Lee H, Weiner RI,. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem 1997; 67: 353-366. (Pubitemid 27509471)
12. Storch CH, Hoeger PH,. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 2010; 163: 269-274.
13. Lamy S, Lachambre M, Lord-Dufour S, et al., Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol 2010; 53: 200-208.
14. Ozeki M, Fukao T, Kondo N,. Propranolol for intractable diffuse lymphangiomatosis. N Engl J Med 2011; 364: 1380-1382.
15. Frischer JS, Huang J, Serur A, et al., Biomolecular markers and involution of hemangiomas. Pediatr Surg 2004; 39: 400-404. (Pubitemid 38338357)